Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma

Takeshi Nonoshita, Yoshiyuki Shioyama, Katsumasa Nakamura, Torahiko Nakashima, Ohga Saiji, Tadamasa Yoshitake, Kayoko Ohnishi, Kotaro Terashima, Kaori Asai, Hiroshi Honda

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.

Original languageEnglish
Pages (from-to)481-484
Number of pages4
JournalJournal of radiation research
Volume51
Issue number4
DOIs
Publication statusPublished - Aug 2 2010

Fingerprint

Chemoradiotherapy
Tongue
toxicity
Squamous Cell Carcinoma
cancer
Mucositis
Carcinoma
radiation therapy
grade
therapy
Radiotherapy
examination
anemias
Deglutition Disorders
Anemia
potassium
Potassium
drugs
tumors
dosage

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Health, Toxicology and Mutagenesis

Cite this

Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma. / Nonoshita, Takeshi; Shioyama, Yoshiyuki; Nakamura, Katsumasa; Nakashima, Torahiko; Saiji, Ohga; Yoshitake, Tadamasa; Ohnishi, Kayoko; Terashima, Kotaro; Asai, Kaori; Honda, Hiroshi.

In: Journal of radiation research, Vol. 51, No. 4, 02.08.2010, p. 481-484.

Research output: Contribution to journalArticle

Nonoshita, T, Shioyama, Y, Nakamura, K, Nakashima, T, Saiji, O, Yoshitake, T, Ohnishi, K, Terashima, K, Asai, K & Honda, H 2010, 'Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma', Journal of radiation research, vol. 51, no. 4, pp. 481-484. https://doi.org/10.1269/jrr.09134
Nonoshita, Takeshi ; Shioyama, Yoshiyuki ; Nakamura, Katsumasa ; Nakashima, Torahiko ; Saiji, Ohga ; Yoshitake, Tadamasa ; Ohnishi, Kayoko ; Terashima, Kotaro ; Asai, Kaori ; Honda, Hiroshi. / Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma. In: Journal of radiation research. 2010 ; Vol. 51, No. 4. pp. 481-484.
@article{f0b7c8eb569046e6993bd4d89dd48887,
title = "Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma",
abstract = "In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4{\%}. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.",
author = "Takeshi Nonoshita and Yoshiyuki Shioyama and Katsumasa Nakamura and Torahiko Nakashima and Ohga Saiji and Tadamasa Yoshitake and Kayoko Ohnishi and Kotaro Terashima and Kaori Asai and Hiroshi Honda",
year = "2010",
month = "8",
day = "2",
doi = "10.1269/jrr.09134",
language = "English",
volume = "51",
pages = "481--484",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "4",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma

AU - Nonoshita, Takeshi

AU - Shioyama, Yoshiyuki

AU - Nakamura, Katsumasa

AU - Nakashima, Torahiko

AU - Saiji, Ohga

AU - Yoshitake, Tadamasa

AU - Ohnishi, Kayoko

AU - Terashima, Kotaro

AU - Asai, Kaori

AU - Honda, Hiroshi

PY - 2010/8/2

Y1 - 2010/8/2

N2 - In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.

AB - In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=77954995293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954995293&partnerID=8YFLogxK

U2 - 10.1269/jrr.09134

DO - 10.1269/jrr.09134

M3 - Article

C2 - 20601829

AN - SCOPUS:77954995293

VL - 51

SP - 481

EP - 484

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 4

ER -